https://scholars.lib.ntu.edu.tw/handle/123456789/581779
標題: | Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction? | 作者: | SHIH-JER HSU Yang S.-S. JIA-HORNG KAO |
關鍵字: | Direct-acting antivirals; Hepatitis C virus; Hepatocellular carcinoma | 公開日期: | 2020 | 出版社: | Elsevier B.V. | 卷: | 119 | 期: | 1P1 | 起(迄)頁: | 3-11 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Although interferon (IFN)-based therapy has been shown to reduce hepatocellular carcinoma (HCC) development once patients with chronic hepatitis C virus (HCV) infection achieve sustained virologic response (SVR), IFN-based therapy is limited by its multiple adverse effects, non-oral administration, and unsatisfactory SVR rate. In recent years, IFN-free all-oral direct-acting antivirals (DAAs) have replaced IFN-based therapy as the standard of care for HCV infection worldwide because of the higher SVR rate and lower incidence of adverse effects. By using currently approved DAA regimens, HCV can be eradicated in more than 95% of infected hosts, regardless of their disease severity. Since 2016, the risk of de novo occurrence or recurrence of HCC in hepatitis C patients receiving DAAs has been debatable because of a report addressing an unexpected high early tumor recurrence rate. To solve this important, interesting, yet controversial issue, we thus reviewed the latest and most relevant articles on this subject and proposed recommendations to manage such patients for healthcare providers. ? 2019 Formosan Medical Association |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85073918809&doi=10.1016%2fj.jfma.2019.09.006&partnerID=40&md5=318796da89185e741f26b0a8e27f4ccd https://scholars.lib.ntu.edu.tw/handle/123456789/581779 |
ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2019.09.006 | SDG/關鍵字: | alpha fetoprotein; antivirus agent; antivirus agent; interferon; antiviral therapy; cancer risk; chronic hepatitis C; clinical practice; computer assisted tomography; disease severity; fatty liver; follow up; health care quality; hepatitis C; Hepatitis C virus; human; immunosuppressive treatment; liver cell; liver cell carcinoma; liver fibrosis; liver graft; liver weight; nonhuman; nuclear magnetic resonance imaging; prediction; recurrent disease; Review; risk factor; sustained virologic response; tumor recurrence; viral clearance; chronic hepatitis C; complication; liver cell carcinoma; liver tumor; virology; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Risk Factors; Sustained Virologic Response |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。